EWA
ABCL icon

EverSource Wealth Advisors’s AbCellera Biologics ABCL Stock Holding History

EverSource Wealth Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,000
Closed -$14.7K – 4011
2024
Q4 		$14.7K Hold
5,000
– – ﹤0.01% 1803
2024
Q3 		$13K Hold
5,000
– – ﹤0.01% 1723
2024
Q2 		$16.3K Buy
+5,000
New +$18.9K ﹤0.01% 1603

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EverSource Wealth Advisors's ABCL Position: Q1 2025 in Review

EverSource Wealth Advisors sold out of AbCellera Biologics (ABCL) in Q1 2025, closing a stake of 5,000 shares — an estimated $14.7K sold.

EverSource Wealth Advisors first reported a position in ABCL in Q2 2024 and held it in 3 quarters. The position peaked at $16.3K in Q2 2024. 129 funds tracked by Wall St. Rank hold ABCL as of Q1 2025.

  • EverSource Wealth Advisors reported no remaining AbCellera Biologics position as of Q1 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 5,000 AbCellera Biologics shares in Q1 2025, an estimated $14.7K.
  • EverSource Wealth Advisors first reported a position in AbCellera Biologics in Q2 2024 and held it in 3 quarters.
  • EverSource Wealth Advisors's AbCellera Biologics position peaked at $16.3K in Q2 2024.
  • 129 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2025.

Based on EverSource Wealth Advisors's 13F filing for Q1 2025, filed 13 May 2025.